Highlights
- Ethics approval received to start CHM CDH17 Phase 1/2 clinical trial.
- The study will be conducted on patients with advanced gastrointestinal (GI) cancers.
- In earlier studies, CHM CDH17 eradicated established tumours in seven cancer models.
Chimeric Therapeutics Limited (ASX: CHM) has achieved a significant milestone with the receipt of ethics approval to commence a multi-site Phase 1/2 clinical trial of CHM CDH17. The trial will focus on patients with advanced gastrointestinal (GI) cancers.
This development marks a significant step forward in initiating the clinical trial under the FDA (Food and Drug Administration) regulations, highlights the company.
About CHM CDH17
CHM CDH17 is a third generation CAR T cell therapy, which is designed to target CDH17, a cancer target linked with poor metastasis and prognosis in the gastrointestinal tumours, such as neuroendocrine tumours, gastric and colorectal cancers.
Image source: Company update
This year, the company intends to undertake Phase 1A trial in neuroendocrine and gastrointestinal tumours.
CHM shares jump
Triggered by the update, CHM shares jumped by over 14% to AU$0.024 apiece during the early morning trading hours on 20 May 2024.